Full Breakdown
Novo Charts 2030 Growth Plan as Patent Expiry Looms Over Semaglutide Franchise
By Drooid · · How we work
Core Event – Capital Markets Day, September 21, 2026
On September 21 2026, Novo Nordisk held a capital-markets presentation in London. CEO Mike Doustdar outlined a strategy to launch more than five “multi-blockbuster” medicines by 2030 and to generate over DKK 150 billion (? $23 billion) in risk-adjusted pipeline sales by 2035. Analysts asked about pricing power, upcoming patent expiries for semaglutide (the active ingredient in Wegovy and Ozempic), and competition from Eli Lilly’s GLP-1 drugs. Novo shares slid as much as 9 % in pre-market trading and later settled 5.4 % lower.
Background & Context
Wegovy’s 2021 launch helped Novo Nordisk reach a market capitalisation exceeding $600 billion in 2023. Semaglutide now accounts for roughly 75 % of Novo’s 2026 sales. Patent protection in the United States ends in 2032 and in Europe in the early 2030s, opening the market to biosimilars. Eli Lilly’s injectable GLP-1 products—Mounjaro, Zepbound and tirzepatide—have already captured a majority share of the injectable space and are projected to outsell Wegovy by more than $7 billion this year (LSEG data).
Official Statements & Responses
Doustdar called the “elephant in the room” the imminent loss of semaglutide exclusivity and said Novo will emerge “a bigger, more diversified company.” He pledged “targeted acquisitions and partnerships” and expansion into cardiovascular, liver, blood-and-endocrine disorders, and oral obesity therapies. Novo also announced a licensing deal with Orbis Medicines valued at up to USD 1.4 billion and a rebranding to the simplified “Novo” brand, while retaining Novo Nordisk A/S as the legal entity.
Conflicting Reports & Gaps
The efficacy of Novo’s next-generation obesity candidate CagriSema is reported differently. Reuters cites a late-stage trial showing a 12.4 % average weight loss versus 9.1 % for Lilly’s tirzepatide, while TradingView references a separate Phase 3 study reporting 23 % versus 25.5 % for tirzepatide. The discrepancy highlights a lack of consensus on comparative performance. Analysts also question whether premium pricing can be sustained once semaglutide loses exclusivity.
What’s Next
- FDA decision on CagriSema expected in Q4 2026.
- Launch of the CagriSema combination targeted for early 2027.
- Further acquisitions or licensing deals anticipated as Novo seeks “bolt-on” assets to diversify its pipeline.
- Monitoring of semaglutide patent expiries in the United States (2032) and Europe (early 2030s).
The upcoming months will test whether Novo’s “third leg” strategy can offset the looming patent cliff and sustain its position in an increasingly crowded GLP-1 market.